A
Alto Neuroscience
Clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform
About Alto Neuroscience
Alto Neuroscience is a cutting-edge startup that operates in the healthcare sector, specifically in the field of psychiatric drug development. The company's primary focus is on creating precision medicines for the brain, a novel approach that is set to revolutionize the psychiatric medication industry. Alto Neuroscience's unique selling proposition is its use of artificial intelligence (AI) to identify brain biomarkers, which are biological measures of mental health conditions.
Read full description
The company's business model is centered around the development and commercialization of these AI-driven, precision psychiatric drugs. They use a data-driven biomarker platform to match the right patient with the right Alto drug. This approach is based on a decade of clinical neuroscience research and leverages a rich in-human data set, making their solutions highly personalized and potentially more effective.
Alto Neuroscience's primary clients are patients suffering from psychiatric conditions who could benefit from a more personalized approach to their medication. The company operates in the pharmaceutical market, which is a multi-billion dollar industry with significant growth potential.
The company generates revenue by developing and selling these precision psychiatric drugs. As a clinical-stage company, they are likely in the process of conducting clinical trials and seeking regulatory approval for their drugs. Once approved, these drugs can be sold to healthcare providers and patients, providing a steady stream of revenue for the company.
In conclusion, Alto Neuroscience is a promising startup in the healthcare sector that is leveraging AI and precision medicine to redefine psychiatric drug development.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Los Altos, United States
- Employees
- 87
- Open positions
- 1
- Dealroom signal
- 84.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Mental Health, Core AI, Precision Medicine, Spinout, Biotech and Pharma
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $120M | — | Perceptive Advisors · Venrock · Driehaus Capital Management · Commodore Capital | ↗ |
| PRIVATE PLACEMENT VCOther financing | Oct 2025 | $50M | — | Commodore Capital · Vestal Point Capital · Vivo Capital · Perceptive Advisors | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Alto Neuroscience is 7.9K monthly website visits, down 50.6% over the last three months. Alto Neuroscience's team grew 13% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Tim Kendall
WPSS.bio
Series A16 investors entered at this stage
Windham Venture Partners
Apeiron Investment Group- APAble Partners
What If Ventures
Rsquared- BIBioverge
Valor Equity Partners
The Sobrato Organization
Novartis
Gaingels- LCLightswitch Capital
Alkeon Capital
Vine Ventures
Korify Capital
Alpha Wave Global
Presight Capital
Series B and later7 investors entered at this stage
K2 HealthVentures
Eli Lilly- AVAlpha Wave Ventures
- ICInVivium Capital
Franklin Templeton Investments
Point72 Ventures
Alexandria Venture Investments
Other known investors9 additional known investors
Commodore Capital
Perceptive Advisors- VCVestal Point Capital
- DIDellora Investments
Driehaus Capital Management
Spruce Street Capital
Stanford University
Venrock
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alto Neuroscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alto Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.